AYRMID PHARMA
PharmaAYRMID PHARMA is a pharmaceutical company focused on Oncology. Key products include APHEXDA.
FDA Novel Drug Designations
(2023)See 1 novel approval →
AYRMID PHARMA's Key Drugs
AYRMID PHARMA's core commercial portfolio centers on APHEXDA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
AYRMID PHARMA's Recent FDA Approvals
New NDA/BLA approvals for AYRMID PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
AYRMID PHARMA's Therapeutic Areas
AYRMID PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AYRMID PHARMA's Top Competitors
AYRMID PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AYRMID PHARMA Pipeline Snapshot
Active clinical trials for AYRMID PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • APHEXDA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-09-08
- Latest
- 2026-03-11
- Applications
- 1